| 1. |
How do NSAIDs protect against colon cancer? |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1139,
1998,
Page 2-2
&NA;,
Preview
|
PDF (865KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
| 2. |
Examining the modest efficacy of acetylcholinesterase inhibitors in AD |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1139,
1998,
Page 3-3
&NA;,
Preview
|
PDF (717KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
| 3. |
Examining the role of tirofiban in unstable coronary disease |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1139,
1998,
Page 4-5
&NA;,
Preview
|
PDF (1419KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
| 4. |
Unrelated disorders undertreated in patients with chronic disease |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1139,
1998,
Page 5-5
&NA;,
Preview
|
PDF (698KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
| 5. |
Formularies can have an impact on antimicrobial resistance |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1139,
1998,
Page 6-6
&NA;,
Preview
|
PDF (788KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
| 6. |
A shot in the arm for patients with cancer-related fatigue? |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1139,
1998,
Page 7-8
Robert Carlson,
Preview
|
PDF (1512KB)
|
|
摘要:
Fatigue is one of the most commonly reported symptoms in patients with cancer, occurring in as many as 90% of those undergoing chemotherapy or radiotherapy. Anaemia is a common cause of fatigue in all patients, and this is frequently exacerbated by the myelosuppressive nature of cancer therapies. Symptomatic anaemia may require palliative intervention with blood transfusions. Treatment with epoetin alfa [recombinant human erythropoietin; Amgen] has become an option for patients with cancer-related anaemia who are receiving myelosuppressive chemotherapy. This intervention can correct the patient's anaemia as well as decrease their transfusion requirements. Experts at the 10th International Symposium on Supportive Care in Cancer [San Antonio, US; March 1998] reported that patients who respond to epoetin alfa appear to have improvements in fatigue and overall quality of life (QOL) that is independent of their tumour response to chemotherapy.
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
| 7. |
Interferon-consensus useful in chronic hepatitis C |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1139,
1998,
Page 8-8
&NA;,
Preview
|
PDF (740KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
| 8. |
Atreleuton protects against exercise-induced asthma |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1139,
1998,
Page 9-9
&NA;,
Preview
|
PDF (728KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
| 9. |
News in brief … |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1139,
1998,
Page 10-10
&NA;,
Preview
|
PDF (768KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
| 10. |
PDE4 inhibitor strategy starts to perform in asthma |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1139,
1998,
Page 11-12
Wayne Elwood,
Preview
|
PDF (1631KB)
|
|
摘要:
The first clinical evidence that a novel bronchodilating anti-inflammatory agent may be on the horizon for treating patients with asthma was presented at the 1998 International Conference of the American Lung Association and the American Thoracic Society [Chicago, US; April 1998]. In a proof-of-concept study, SmithKline Beecham's second-generation, selective, oral phosphodiesterase type 4 (PDE4) inhibitor, SB-207499 [‘Ariflo’; phase II], attenuated exercise-induced bronchoconstriction in patients with asthma. Additional information supporting this novel agent's favourable tolerability profile after repeated administration was also presented at the meeting.
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
首页
